Alphabet Inc, the parent company of Google, is introducing a new venture by the name of Isomorphic Labs that will put artificial intelligence to good use for the discovery of new medicines.
With an AI-first approach, Isomorphic Labs is a new Alphabet company that promises to "reimagine the entire drug discovery process." In a highly collaborative environment, the company will leverage biology, medicinal chemistry, biophysics, engineering and more to approach drug discovery like never before.
This start-up will fall under the company’s London research laboratory, DeepMind. Already, algorithms from DeepMind have been helpful for predicting the shapes of proteins (with atomic-level accuracy) and this technology has the potential to be an asset for studying and inventing the future of medicine.